Amuvatinib
| Code | Size | Price |
|---|
| SYN-1056-M100 | 100 mg | Enquire |
Quantity:
| SYN-1056-M001 | 1 mg | £127.00 |
Quantity:
| SYN-1056-M005 | 5 mg | £233.00 |
Quantity:
| SYN-1056-M010 | 10 mg | £379.00 |
Quantity:
| SYN-1056-M050 | 50 mg | £1,006.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
MP-470
Appearance:
Solid.
CAS:
850879-09-3
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)
InChiKey:
FOFDIMHVKGYHRU-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 850879-09-3. Formula: C23H21N5O3S. MW: 447.5. Amuvatinib is a potent, novel and orally active multi-targeted tyrosine kinase inhibitor, which inhibits a number of validated tumor targets including c-kit, PDGFRalpha and flt3, with IC(50) values of 10nM, 40nM and 81nM respectively.
Molecular Formula:
C23H21N5O3S
Molecular Weight:
447.5
Package Type:
Plastic Vial
Product Description:
Amuvatinib is a potent, novel and orally active multi-targeted tyrosine kinase inhibitor, which inhibits a number of validated tumor targets including c-kit, PDGFRalpha and flt3, with IC(50) values of 10nM, 40nM and 81nM respectively.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer: W. Qi, et al.; BMC Cancer 9, 142 (2009)
Related Products
| Product Name | Product Code | Supplier | Genistein | AG-CN2-0427 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|